These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7147211)

  • 1. Desialylation of fibrinogen with neuraminidase. Kinetic and clotting studies.
    Diaz-Mauriño T; Castro C; Albert A
    Thromb Res; 1982 Aug; 27(4):397-403. PubMed ID: 7147211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sialic acid in fibrinogen: effects of sialic acid on fibrinogen-fibrin conversion by thrombin and properties of asialofibrin clot.
    Okude M; Yamanaka A; Morimoto Y; Akihama S
    Biol Pharm Bull; 1993 May; 16(5):448-52. PubMed ID: 8364489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sialic acid and enzymatic desialation of cord blood fibrinogen.
    Francis JL; Armstrong DJ
    Haemostasis; 1982; 11(4):223-8. PubMed ID: 7129234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains.
    Martinez J; MacDonald KA; Palascak JE
    Blood; 1983 Jun; 61(6):1196-202. PubMed ID: 6839020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of pH on the generation of turbidity and elasticity associated with fibrinogen-fibrin conversion by thrombin are remarkably influenced by sialic acid in fibrinogen.
    Okude M; Yamanaka A; Akihama S
    Biol Pharm Bull; 1995 Feb; 18(2):203-7. PubMed ID: 7742784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of fibrinogen and asialofibrinogen with concanavalin A and clotting properties of the complexes.
    Diaz-Mauriño T; Albert A
    Biochim Biophys Acta; 1981 Nov; 677(3-4):381-9. PubMed ID: 7295803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Participation of sialic acid residue in the fibrinogen-fibrin conversion by thrombin].
    Akihama S; Matsuda Y; Fukase T; Yamanaka A; Okude M
    Yakugaku Zasshi; 1995 Jul; 115(7):537-42. PubMed ID: 7562401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sialic acid dependent polypeptide chain heterogeneity of human fibrinogen demonstrated by two-dimensional electrophoresis.
    Kuyas C; Haeberli A; Straub PW
    Thromb Haemost; 1982 Feb; 47(1):19-21. PubMed ID: 7071802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen and fibrin interaction with concanavalin A dimer and its influence on coagulation.
    Díaz-Mauriño T; Blanco R; Albert A
    Biochim Biophys Acta; 1984 May; 799(1):45-50. PubMed ID: 6722179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of sodium citrate in the dysfibrinogenaemia of liver disease.
    Francis JL; Watson NJ; Simmonds VJ
    Thromb Res; 1984 May; 34(3):187-97. PubMed ID: 6729777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products.
    Vila V; Regañón E; Aznar J; Navarro G; Salas M
    Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 patient fibrinogen produces dense clots with altered polymerization kinetics, partially explained by increased sialic acid.
    Moiseiwitsch N; Zwennes N; Szlam F; Sniecinski R; Brown A
    J Thromb Haemost; 2022 Dec; 20(12):2909-2920. PubMed ID: 36111490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and metabolic properties of human asialofibrinogen.
    Martinez J; Palascak J; Peters C
    J Lab Clin Med; 1977 Feb; 89(2):367-77. PubMed ID: 833473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen-bound sialic acid levels in the dysfibrinogenaemia of liver disease.
    Francis JL; Armstrong DJ
    Haemostasis; 1982; 11(4):215-22. PubMed ID: 6290353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sialic acid removal on human low density lipoprotein catabolism in vivo.
    Malmendier CL; Delcroix C; Fontaine M
    Atherosclerosis; 1980 Oct; 37(2):277-84. PubMed ID: 7426100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonclottable fibrin obtained from partially reduced fibrinogen: characterization and tissue plasminogen activator stimulation.
    Procyk R; Medved L; Engelke KJ; Kudryk B; Blombäck B
    Biochemistry; 1992 Mar; 31(8):2273-8. PubMed ID: 1540582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identical behavior of fibrinogen and asialo-fibrinogen in reactions with platelets during ADP-induced aggregation.
    Harfenist EJ; Packham MA; Mustard JF
    Thromb Res; 1980 Nov; 20(3):353-8. PubMed ID: 7209886
    [No Abstract]   [Full Text] [Related]  

  • 18. Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease.
    Martinez J; Palascak JE; Kwasniak D
    J Clin Invest; 1978 Feb; 61(2):535-8. PubMed ID: 621288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of calcium binding and of EDTA and CaEDTA on the clotting of bovine fibrinogen by thrombin.
    Perizzolo KE; Sullivan S; Waugh DF
    Arch Biochem Biophys; 1985 Mar; 237(2):520-34. PubMed ID: 3919650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fibrinogen sialic acid residues on ex vivo platelet deposition on biomaterials.
    Park K; Gerndt SJ; Cooper SL
    Thromb Res; 1986 Aug; 43(3):293-302. PubMed ID: 3738866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.